Celea Therapeutics, Inc. will present data from its deupirfenidone (LYT-100) program at the European Respiratory Society Congress in Barcelona, Spain ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE